Abstract
Hormone replacement therapy (HRT) is a highly cost-effective treatment for symptoms of the menopause such as hot flushes (flashes). A number of economic evaluations have indicated that it may also be a cost-effective therapy for the prevention of cardiovascular disease and osteoporosis. However, these evaluations are based on the premise that HRT will reduce cardiovascular disease by 30 to 50%. Recent evidence casts doubt on its effectiveness at preventing cardiovascular disease, certainly as a secondary preventive therapy. Furthermore, HRT is likely to increase the incidence of breast cancer. If the effect of HRT on the cardiovascular system is slight or nonexistent, but its effect on breast cancer is modest or strong, then HRT is unlikely to be a cost-effective treatment for asymptomatic women at low risk of osteoporosis. However, the unwanted effects of HRT on the breast may be significantly reduced by targeting therapy to those women with low bone mass and who have other risk factors for fracture. Such a strategy is likely to be more cost effective than a strategy which allows asymptomatic women with low fracture risk to take HRT in the long term. As selective estrogen receptor modulators (SERMs) aggravate menopausal symptoms they are not likely to be an alternative for most perimenopausal women. Therefore, SERMs are more likely to be a competitor to existing and forthcoming bisphosphonates rather than HRT.
| Original language | English |
|---|---|
| Pages (from-to) | 916 |
| Number of pages | 8 |
| Journal | Pharmacoeconomics |
| Volume | 16 |
| Issue number | 1 |
| Publication status | Published - Jul 1999 |
Keywords
- BONE-MINERAL DENSITY
- QUALITY-OF-LIFE
- POSTMENOPAUSAL WOMEN
- OSTEOPOROTIC FRACTURES
- COST-EFFECTIVENESS
- RANDOMIZED TRIAL
- BREAST-CANCER
- HIP FRACTURE
- OLDER WOMEN
- ESTROGEN